Innovation of multi-Drug delivery platform based on the ssPalm: Immune-engineering and cancer therapy
| Project/Area Number |
15H01806
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Chiba University (2016-2017)
Hokkaido University (2015) |
|---|
Principal Investigator |
Hidetaka Akita 千葉大学, 大学院薬学研究院, 教授 (80344472)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥40,430,000 (Direct Cost: ¥31,100,000、Indirect Cost: ¥9,330,000)
Fiscal Year 2017: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2016: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2015: ¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
|
|---|
| Keywords | 癌免疫 / ナノ粒子 / 環境応答性材料 / ワクチン / DNA / ナノ材料 / 遺伝子 / 薬学 / ＤＮＡ / ナノバイオ / ナノマシン / 癌免役 / ドラッグデリバリーシステム / 癌 |
|---|
| Outline of Final Research Achievements |
For the success of the cancer immune therapy, activation of antigen-specific cytotoxic T cell (CTL) is quite important. DNA vaccine is principally useful technology to induce this CTL activity. Meanwhile, the intra-tumor region is considered to be an immune-suppressive environment. Thus, for the effective function of the cancer vaccine, the normalization/ neutralization of the immune-suppressive machinery is essential in parallel.
Currently, we have developed a lipid nanoparticle composed of intracellular environment-responsive material (ss-cleavable and pH-activated lipid-like material: ssPalm) as a technology to overcome the biomembranes barrier, and spontaneous collapse. In this project, we developed a delivery system of Genes, and small compounds using ssPalm as a fundamental platform, and applied them for the immune-engineering for cancer therapy.
|
Report
(3 results)
Research Products
(25 results)
